rts logo

Will Amylyx Pharmaceuticals Inc (AMLX) benefit from Wall Street bulls Calls?

Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) is -80.71% lower on its value in year-to-date trading and has touched a low of $2.67 and a high of $31.77 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AMLX stock was last observed hovering at around $2.88 in the last trading session, with the day’s loss setting it -0.04%.

Currently trading at $2.84, the stock is -63.76% and -77.59% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.88 million and changing -1.39% at the moment leaves the stock -83.40% off its SMA200. AMLX registered -90.69% loss for a year compared to 6-month gain of -84.81%. The firm has a 50-day simple moving average (SMA 50) of -$0.46 and a 200-day simple moving average (SMA200) of -$4.38.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The stock witnessed a -85.49% loss in the last 1 month and extending the period to 3 months gives it a -80.47%, and is -1.05% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.14% over the week and 10.04% over the month.

Amylyx Pharmaceuticals Inc (AMLX) has around 384 employees, a market worth around $192.50M and $380.79M in sales. Current P/E ratio is 4.03. Profit margin for the company is 12.94%. Distance from 52-week low is 6.37% and -91.06% from its 52-week high. The company has generated returns on investments over the last 12 months (11.32%).

Amylyx Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at $0 with sales reaching $99.47M over the same period.The EPS is expected to shrink by -283.95% this year, but quarterly earnings will post -53.00% year-over-year. Quarterly sales are estimated to grow 39.30% in year-over-year returns.

Amylyx Pharmaceuticals Inc (AMLX) Top Institutional Holders

243 institutions hold shares in Amylyx Pharmaceuticals Inc (AMLX), with institutional investors hold 122.16% of the company’s shares. The shares outstanding are 67.71M, and float is at 47.57M with Short Float at 10.70%. Institutions hold 104.77% of the Float.

The top institutional shareholder in the company is Vanguard Group Inc with over 4.93 million shares valued at $106.25 million. The investor’s holdings represent 7.31% of the AMLX Shares outstanding. As of Jun 29, 2023, the second largest holder is Perceptive Advisors Llc with 4.87 million shares valued at $105.13 million to account for 7.23% of the shares outstanding. The other top investors are Blackrock Inc. which holds 3.51 million shares representing 5.20% and valued at over $75.61 million, while Viking Global Investors, L.P. holds 4.40% of the shares totaling 2.96 million with a market value of $63.9 million.

Amylyx Pharmaceuticals Inc (AMLX) Insider Activity

The most recent transaction is an insider sale by Klee Justin B.,the company’sCo-Chief Executive Officer. SEC filings show that Klee Justin B. sold 4,135 shares of the company’s common stock on Mar 05 ’24 at a price of $18.73 per share for a total of $77440.0. Following the sale, the insider now owns 2.96 million shares.

Amylyx Pharmaceuticals Inc disclosed in a document filed with the SEC on Mar 05 ’24 that Cohen Joshua B (Co-Chief Executive Officer) sold a total of 4,135 shares of the company’s common stock. The trade occurred on Mar 05 ’24 and was made at $18.73 per share for $77440.0. Following the transaction, the insider now directly holds 3.02 million shares of the AMLX stock.

Still, SEC filings show that on Mar 05 ’24, FRATES JAMES M (Chief Financial Officer) disposed off 1,792 shares at an average price of $18.73 for $33560.0. The insider now directly holds 134,784 shares of Amylyx Pharmaceuticals Inc (AMLX).

Related Posts